title: Intravenously administered 2'-deoxycytidine suppresses mouse myeloma tumor growth.
abstract: We examined the in vivo effects of intravenously administered 2'-deoxycytidine (dCyd) on tumor growth and survival time in mice bearing SP2/0-Ag14 (SP2/0) myeloma tumors. Administration of dCyd tended to decrease the tumor volume and significantly decreased the tumor weight. A single intravenous administration of dCyd significantly increased survival time of the tumor-bearing mice. The effect of dCyd on tumor growth was maintained for at least 1 week after the final administration. The net amount of dCyd in the kidney, liver, and spleen of the tumor-bearing mice increased 2.5 to 5.3 fold compared with the amount in non-tumor-bearing mice. Our results suggest that the increase in dCyd in the mice inoculated SP2/0 myeloma cells plays an important role for the growth suppression of the tumor.
authors.affiliation: Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan. ayano@pharm.setsunan.ac.jp
authors.forename: Ayano
authors.initials: A
authors.lastname: Iwazaki
authors.forename: Kimie
authors.initials: K
authors.lastname: Imai
authors.forename: Kunio
authors.initials: K
authors.lastname: Nakanishi
authors.forename: Masanori
authors.initials: M
authors.lastname: Yoshioka
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005472:Fluorouracil / Q000627:therapeutic use; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013154:Spleen / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D005472:Fluorouracil